ROQUEFORT THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.41 GBX | -7.16% |
|
-7.16% | -39.17% |
| Apr. 05 | Roquefort cancels fundraise after "unusual" stock movements | AN |
| Apr. 05 | Roquefort Therapeutics Shelves Potential Placing Following Unusual Price Movements | MT |
| Sales 2021 | 637 797.62 | Sales 2022 | - | Capitalization | 8.56M 10.71M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | -1M -1.25M | EV / Sales 2021 | 10,439 x |
| Net cash position 2021 | 900K 1.13M | Net cash position 2022 | 2.32M 2.91M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-3.77
x | P/E ratio 2022 |
-4.24
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.02% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -7.16% | ||
| 1 week | -7.16% | ||
| Current month | -37.00% | ||
| 1 month | -39.17% | ||
| 3 months | -34.67% | ||
| 6 months | -40.20% | ||
| Current year | -39.17% |
1 week
4.41
4.75
1 month
3.857.50
Current year
3.859.50
1 year
3.859.50
3 years
3.8513.63
5 years
3.8513.63
10 years
3.8513.63
| Managers | Title | Age | Since |
|---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
| Chairman | 51 | 20-08-16 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 22-09-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 22-04-04 |
Darrin Disley
BRD | Director/Board Member | 57 | 22-09-15 |
| Chairman | 51 | 20-08-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 4.41 | -7.16% | 225 000 |
| 24-04-24 | 4.75 | 0.00% | 500,000 |
| 24-04-23 | 4.75 | 0.00% | 1,373 |
| 24-04-22 | 4.75 | 0.00% | 96,452 |
| 24-04-19 | 4.75 | 0.00% | 0 |
Delayed Quote London S.E., April 25, 2024 at 04:50 am EDT
More quotes
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
Calendar
2024-05-07
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -39.17% | 7.63M | |
| -6.04% | 113B | |
| -3.41% | 87.84B | |
| +20.96% | 64.04B | |
| +4.46% | 61.27B | |
| +11.34% | 43.34B | |
| +8.70% | 41.12B | |
| +17.80% | 34.17B | |
| +3.13% | 24.84B | |
| -4.09% | 22.4B |
- Stock Market
- Equities
- ROQ Stock
